Stocks traded mostly lower Friday, weighed down by a mixed batch of earnings results, disappointing economic data and a lack of progress on Capitol Hill toward another coronavius aid package.

Inspired by blowout earnings from tech heavyweights Apple, Amazon, Facebook and Google parent Alphabet, stocks rallied at the open, but slipped into mostly negative territory during the session.

What are major benchmarks doing?

The Dow Jones Industrial Average
DJIA,
+0.43%

fell about 208 points, or 0.8%, to trade near 26,105, while the S&P 500
SPX,
+0.76%

was off 16 points, or 0.5%, at 3,230. The tech-heavy Nasdaq Composite
COMP,
+1.48%

slipped briefly into negative territory in the early afternoon, but was up 17 points or 0.2%, to trade near 10,605, at last reading.

The Dow on Thursday fell 225.92 points, or 0.9%, to end at 26,313.65, while the S&P 500 lost 12.22 points, or 0.4%, to close at 3,246.22. The Nasdaq Composite rose 44.87 points, or 0.4%, to finish at 10,587.81.

For the week, the Dow is on track to lose 1.4%, the S&P 500 looks set to close 0.5% higher, and the Nasdaq is on pace to jump 2.3%.

What’s driving the market?

Tech earnings were in focus following results from some of the industry’s largest and most powerful players after Thursday’s closing bell, including Apple Inc.
AAPL,
+10.46%
,
Facebook Inc.
FB,
+8.17%
,
Amazon.com Inc.
AMZN,
+3.69%

and Google parent Alphabet Inc.
GOOGL,
-3.27%

GOOG,
-3.16%
.

Read:Pandemic? Antitrust? No worries for Big Tech, which racked up $200 billion in sales anyway

Need to Know:Apple and Amazon to dominate an economy ‘without mouths or noses’ but 10% of jobs may never come back, strategist says

But it was a different story outside the tech sector.

“This morning the mood was mixed with a plethora of earnings results. Exxon had its worst quarterly loss in modern history, while Chevron’s results were the worst in three decades,” said Edward Moya, analyst at Oanda, in a note.

Stocks softened after a downbeat reading on U.S. consumer sentiment. The final reading of the University of Michigan’s consumer sentiment index in July slipped to 72.5 from an initial 72.9. The index registered 73.2 in June.

“The deterioration in consumer sentiment along with a failure to extend full emergency unemployment benefits will weigh on consumer spending,” said Nancy Vanden Houten, lead economist at Oxford Economics. “We do expect policy makers to approve another round of direct payments to households, but that will provide only temporary relief.”

There was little sign of progress in talks between congressional Democrats, Republicans and the White House on a new coronavirus relief bill with expanded unemployment benefits due to expire Friday. Democrats rejected a White House proposal to temporarily extend the $600-a-week in added benefits, saying the Trump administration didn’t understand the severity of the crisis. Talks between Trump administration officials and congressional Democrats could stretch into the weekend, White House chief of staff Mark Meadows told reporters Friday morning.

Peter Andersen, founder of Boston-based Andersen Capital Management, thinks investors should take some comfort from the unprecedented messaging coming from policy makers, both monetary and fiscal. While the details of another aid package aren’t finalized yet, Andersen said in an interview, Washington is sending “signals” that it will support the economy.

“In a moment when we can’t be analytical, it’s important to be psychological,” he said. “I’m thrilled that the Fed came out and said, we’re going to keep rates low. I just think the market is positioned for a tremendous rally when the consumer emerges from lockdown with a vaccine, low gas prices and ultra-low interest rates.”

Still, the drumbeat of bad news continues, for now. The U.S. saw record deaths from COVID-19 in Texas, Florida and Arizona, while California faced its second-deadliest day.

In vaccine news, European drugmaker Sanofi
SNY,
-0.09%

said the U.S. government will pay up to $2.1 billion for the COVID-19 vaccine candidate it is developing with GlaxoSmithKline
GSK,
+0.17%
.
The funding, part of Operation Warp Speed, will be used to support ongoing clinical development and manufacturing of the experimental candidate, with at least 100 million doses promised to the U.S.

U.S. consumer spending rose 5.6% in June, while personal incomes declined by 1.1%, government data showed, but spending may be slowing again in July given unemployment benefit claims are edging up again in weekly data. A related measure of core inflation, the Federal Reserve’s favorite gauge of price pressures, rose 0.2%, in line with expectations. The employment cost index for the second quarter rose 0.5%, versus expectations for a 0.6% rise.

Which companies are in focus?
What are other markets doing?

In Asia, China’s CSI 300 index
000300,
+0.83%

rose 0.8%, the Shanghai Composite
SHCOMP,
+0.70%

rose 0.7%, Hong Kong’s Hang Seng Index
HSI,
-0.46%

fell 0.5% and Japan’s Nikkei 225
NIK,
-2.81%

slumped 2.8%.

Stocks closed lower in Europe, with the Stoxx 600 Europe index
SXXP,
-0.88%

down 0.9% at 356.33, while the U.K.’s FTSE 100
UKX,
-1.54%

fell 1.5% to close at 5,897.76.

Gold futures
GCQ20,
+1.54%

were on the rise, up more than 1% to $1,963.00 an ounce. The ICE U.S. Dollar Index
DXY,
+0.46%

edged up 0.4% but remained on track for its biggest monthly fall since 2010. Oil futures were higher, with the U.S. benchmark
CLU20,
+1.25%

up 0.9% to $40.26 a barrel on the New York Mercantile Exchange.

The yield on the 10-year Treasury note
TMUBMUSD10Y,
0.535%

fell 1 basis point to 0.544%. Yields move in the opposite direction of prices.

See: 10-year Treasury yield plunged to its lowest in 234 years, says Deutsche Bank



Source link